Is WHWK or MNPR more profitable?

Monopar Therapeutics' return on equity of -12.91% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -58.46% -53.81% Monopar Therapeutics N/A -12.91% -12.66%

Does the media prefer WHWK or MNPR?

In the previous week, Monopar Therapeutics had 10 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 14 mentions for Monopar Therapeutics and 4 mentions for Whitehawk Therapeutics. Monopar Therapeutics' average media sentiment score of 1.00 beat Whitehawk Therapeutics' score of 0.72 indicating that Monopar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is WHWK or DRUG more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -58.46% -53.81% Bright Minds Biosciences N/A -20.58% -20.25%

Does the media refer more to WHWK or DRUG?

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Whitehawk Therapeutics and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.97 beat Whitehawk Therapeutics' score of 0.72 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is WHWK or CADL more profitable?

Whitehawk Therapeutics' return on equity of -58.46% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -58.46% -53.81% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to WHWK or CADL?

In the previous week, Candel Therapeutics had 14 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 18 mentions for Candel Therapeutics and 4 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Candel Therapeutics' score of -0.02 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer PHAR or WHWK?

In the previous week, Pharming Group had 4 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 8 mentions for Pharming Group and 4 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Pharming Group's score of 0.46 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RIGL or WHWK?

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 4 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Rigel Pharmaceuticals' score of 0.38 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Whitehawk Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Whitehawk Therapeutics (WHWK) Competitors

$4.46 -0.22 (-4.70%)

As of 10:43 AM Eastern

Compare

WHWK vs. MNPR, DRUG, CADL, PHAR, and RIGL

Should you buy Whitehawk Therapeutics stock or one of its competitors? Whitehawk Therapeutics's main competitors and comparable companies include Monopar Therapeutics (MNPR), Bright Minds Biosciences (DRUG), Candel Therapeutics (CADL), Pharming Group (PHAR), and Rigel Pharmaceuticals (RIGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Whitehawk Therapeutics compare to Monopar Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Monopar Therapeutics' return on equity of -12.91% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-58.46%	-53.81%
Monopar Therapeutics	N/A	-12.91%	-12.66%

Monopar Therapeutics has lower revenue, but higher earnings than Whitehawk Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	35.61	-$20.60M	-$1.12	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Monopar Therapeutics had 10 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 14 mentions for Monopar Therapeutics and 4 mentions for Whitehawk Therapeutics. Monopar Therapeutics' average media sentiment score of 1.00 beat Whitehawk Therapeutics' score of 0.72 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Whitehawk Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Whitehawk Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 83.86%. Monopar Therapeutics has a consensus price target of $117.42, suggesting a potential upside of 7.63%. Given Whitehawk Therapeutics' higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Monopar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Monopar Therapeutics beats Whitehawk Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Bright Minds Biosciences?

Whitehawk Therapeutics (NASDAQ:WHWK) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Bright Minds Biosciences has lower revenue, but higher earnings than Whitehawk Therapeutics. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	35.61	-$20.60M	-$1.12	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

In the previous week, Whitehawk Therapeutics had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Whitehawk Therapeutics and 2 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.97 beat Whitehawk Therapeutics' score of 0.72 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Whitehawk Therapeutics presently has a consensus price target of $8.20, suggesting a potential upside of 83.86%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 85.10%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Bright Minds Biosciences is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Bright Minds Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Whitehawk Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.27, indicating that its share price is 627% less volatile than the broader market.

52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bright Minds Biosciences' return on equity of -20.58% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-58.46%	-53.81%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Summary

Whitehawk Therapeutics and Bright Minds Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, Candel Therapeutics had 14 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 18 mentions for Candel Therapeutics and 4 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Candel Therapeutics' score of -0.02 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	2 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Whitehawk Therapeutics has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market.

Whitehawk Therapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Whitehawk Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	35.61	-$20.60M	-$1.12	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Whitehawk Therapeutics' return on equity of -58.46% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-58.46%	-53.81%
Candel Therapeutics	N/A	-60.42%	-41.33%

Whitehawk Therapeutics currently has a consensus price target of $8.20, indicating a potential upside of 83.86%. Candel Therapeutics has a consensus price target of $18.57, indicating a potential upside of 62.65%. Given Whitehawk Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Whitehawk Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Whitehawk Therapeutics beats Candel Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Pharming Group?

Pharming Group (NASDAQ:PHAR) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Pharming Group presently has a consensus price target of $38.67, indicating a potential upside of 224.41%. Whitehawk Therapeutics has a consensus price target of $8.20, indicating a potential upside of 83.86%. Given Pharming Group's higher probable upside, research analysts plainly believe Pharming Group is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Pharming Group has a net margin of 2.51% compared to Whitehawk Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Whitehawk Therapeutics	N/A	-58.46%	-53.81%

In the previous week, Pharming Group had 4 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 8 mentions for Pharming Group and 4 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Pharming Group's score of 0.46 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13M	2.24	$2.85M	$0.12	99.33
Whitehawk Therapeutics	$7.14M	35.61	-$20.60M	-$1.12	N/A

Pharming Group has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pharming Group beats Whitehawk Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Whitehawk Therapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Rigel Pharmaceuticals has higher revenue and earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	2.63	$367.02M	$16.32	2.56
Whitehawk Therapeutics	$7.14M	35.61	-$20.60M	-$1.12	N/A

Rigel Pharmaceuticals has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Whitehawk Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Rigel Pharmaceuticals currently has a consensus price target of $54.50, indicating a potential upside of 30.30%. Whitehawk Therapeutics has a consensus price target of $8.20, indicating a potential upside of 83.86%. Given Whitehawk Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Whitehawk Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Whitehawk Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Whitehawk Therapeutics	N/A	-58.46%	-53.81%

In the previous week, Rigel Pharmaceuticals had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 6 mentions for Rigel Pharmaceuticals and 4 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 0.72 beat Rigel Pharmaceuticals' score of 0.38 indicating that Whitehawk Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Whitehawk Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats Whitehawk Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Whitehawk Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WHWK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WHWK vs. The Competition

Export

Metric	Whitehawk Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$254.27M	$3.69B	$6.96B	$13.10B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-3.98	10.23	269.57	25.32
Price / Sales	35.61	1,285.96	595.01	100.00
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.54	17.54	13.06	6.29
Net Income	-$20.60M	-$13.32M	$3.45B	$347.70M
7 Day Performance	-6.30%	0.19%	0.47%	0.89%
1 Month Performance	17.06%	-0.03%	1.11%	0.85%
1 Year Performance	175.31%	53.11%	66.38%	20.25%

Whitehawk Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WHWK Whitehawk Therapeutics	2.3376 of 5 stars	$4.46 -4.7%	$8.20 +83.9%	+173.7%	$254.27M	$7.14M	N/A	21
MNPR Monopar Therapeutics	2.1298 of 5 stars	$120.21 +0.8%	$112.08 -6.8%	+229.5%	$798.73M	N/A	N/A	10	Earnings Report Analyst Forecast Analyst Revision Gap Down
DRUG Bright Minds Biosciences	2.9563 of 5 stars	$80.80 +1.0%	$143.83 +78.0%	+92.4%	$778.57M	N/A	N/A	N/A
CADL Candel Therapeutics	1.8219 of 5 stars	$10.58 +1.1%	$18.57 +75.5%	+84.4%	$766.41M	N/A	N/A	60	Trending News Earnings Report Analyst Forecast Analyst Revision
PHAR Pharming Group	3.7508 of 5 stars	$10.69 +0.0%	$38.67 +261.9%	+9.8%	$755.56M	$376.13M	89.04	280	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WHWK) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. MNPR, DRUG, CADL, PHAR, and RIGL

How does Whitehawk Therapeutics compare to Monopar Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Bright Minds Biosciences?

Summary

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Summary

How does Whitehawk Therapeutics compare to Pharming Group?

Summary

How does Whitehawk Therapeutics compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Whitehawk Therapeutics (WHWK) Competitors

WHWK vs. MNPR, DRUG, CADL, PHAR, and RIGL

How does Whitehawk Therapeutics compare to Monopar Therapeutics?

Is WHWK or MNPR more profitable?

Which has better earnings and valuation, WHWK or MNPR?

Does the media prefer WHWK or MNPR?

Do insiders and institutionals hold more shares of WHWK or MNPR?

Which has more risk and volatility, WHWK or MNPR?

Do analysts prefer WHWK or MNPR?

Summary

How does Whitehawk Therapeutics compare to Bright Minds Biosciences?

Which has better valuation & earnings, WHWK or DRUG?

Does the media refer more to WHWK or DRUG?

Do analysts prefer WHWK or DRUG?

Which has more risk & volatility, WHWK or DRUG?

Do insiders & institutionals hold more shares of WHWK or DRUG?

Is WHWK or DRUG more profitable?

Summary

How does Whitehawk Therapeutics compare to Candel Therapeutics?

Does the media refer more to WHWK or CADL?

Which has more volatility & risk, WHWK or CADL?

Which has better earnings & valuation, WHWK or CADL?

Do institutionals and insiders have more ownership in WHWK or CADL?

Is WHWK or CADL more profitable?

Do analysts prefer WHWK or CADL?

Summary

How does Whitehawk Therapeutics compare to Pharming Group?

Do analysts recommend PHAR or WHWK?

Is PHAR or WHWK more profitable?

Does the media prefer PHAR or WHWK?

Which has stronger valuation & earnings, PHAR or WHWK?

Which has more risk and volatility, PHAR or WHWK?

Do insiders & institutionals have more ownership in PHAR or WHWK?

Summary

How does Whitehawk Therapeutics compare to Rigel Pharmaceuticals?

Which has preferable valuation and earnings, RIGL or WHWK?

Which has more volatility & risk, RIGL or WHWK?

Do analysts rate RIGL or WHWK?

Do insiders and institutionals believe in RIGL or WHWK?

Is RIGL or WHWK more profitable?

Does the media refer more to RIGL or WHWK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK vs. The Competition

Whitehawk Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools